grant
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
Organization BECKMAN RESEARCH INSTITUTE/CITY OF HOPELocation DUARTE, UNITED STATESPosted 1 Sept 2023Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025AGE receptorAblationAddressAlzheimer's disease patientAlzheimer's patientAttenuatedBBB crossingBasal Transcription FactorBasal transcription factor genesBrain CancerCAGBCGCBCancersCell BodyCell Communication and SignalingCell SignalingCellsChronicClinical TrialsCombined Modality TherapyDataDevelopmentDiagnosisDoseDown-RegulationDrugsDysfunctionEffector CellEndothelial CellsFunctional disorderFutureGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGeneticGlial Cell TumorsGlial NeoplasmGlial TumorGlioblastomaGliomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGrowthHeterogeneityHumanImmuneImmune GlobulinsImmune mediated therapyImmune responseImmunesImmunochemical ImmunologicImmunoglobulinsImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyInfiltrationInflammationInflammatoryIntracellular Communication and SignalingInvadedKO miceKnock-out MiceKnockout MiceLIAGLigandsMAC387MRP14MacrophageMalignant NeoplasmsMalignant TumorMalignant Tumor of the BrainMalignant neoplasm of brainMeasuresMediatingMedicationMembraneMesenchymalMiceMice MammalsModelingModern ManMolecularMultimodal TherapyMultimodal TreatmentMurineMusMφNeuroglial NeoplasmNeuroglial TumorNull MouseOncogenicPD 1PD-1PD1Pathway interactionsPatientsPattern recognition receptorPharmaceutical PreparationsPhysiopathologyProcessProteinsRAGE receptorRadiation therapyRadiotherapeuticsRadiotherapyReceptor ActivationReceptor InhibitionReceptor ProteinRegimenReportingResistanceRoleS100A9S100A9 geneSecondary toSignal PathwaySignal TransductionSignal Transduction SystemsSignalingT cell infiltrationT-CellsT-LymphocyteTestingTissue GrowthTranscription Factor Proto-OncogeneTranscription factor genesTumor Cell InvasionTumor InvasionWNT Signaling PathwayWNT signalingadvanced glycosylation end product receptoramphoterin receptoranti-tumor immune responseattenuateattenuatesbiological signal transductionblood-brain barrier crossingbloodbrain barrier crossingcancer microenvironmentcheck point blockadecheckpoint blockadecombination therapycombined modality treatmentcombined treatmentcytokinedevelopmentaldrug/agentexhaustexhaustionglial-derived tumorglioblastoma multiformeglycationhost responseimmune check point blockadeimmune checkpoint blockadeimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimprovedinflammatory environmentinflammatory milieuinhibitormalignancymembermembrane structuremulti-modal therapymulti-modal treatmentneoplasm/cancerneuroglia neoplasmneuroglia tumornew approachesnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-enzymatic glycosylationnonenzymatic glycosylationnovelnovel approachesnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel strategiesnovel strategynovel therapeuticsnovel therapyontogenyoxidationpathophysiologypathwaypatient living with Alzheimer's diseasepatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseasepermissivenesspre-clinical studypreclinical studyprogrammed cell death 1programmed cell death protein 1programmed death 1radiation treatmentreceptorreceptor for AGEreceptor for advanced glycation end productreceptor for advanced glycation endproductsreceptor of AGEresistance mechanismresistance to therapyresistantresistant mechanismresistant to therapyresponsesle2small moleculesocial rolespongioblastoma multiformesuccesssynergismsystemic lupus erythematosus susceptibility 2targeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistantthymus derived lymphocytetranscription factortreatment resistancetreatment with radiationtumortumor growthtumor microenvironment
Description preview
PROJECT SUMMARY
Patients diagnosed with glioblastoma (GBM) have a median overall survival of less than two years even
after receiving multimodal therapies. Multiple factors account for this treatment resistance including: 1) Inability
of therapies to cross the blood-brain barrier to reach invading cells; 2) GBM’s molecular heterogeneity and…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click